<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01842126</url>
  </required_header>
  <id_info>
    <org_study_id>103NS103</org_study_id>
    <secondary_id>2012-005224-15</secondary_id>
    <nct_id>NCT01842126</nct_id>
  </id_info>
  <brief_title>Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)</brief_title>
  <official_title>Study of Safety, Tolerability, and Pharmacokinetics of BG00010 (Neublastin) Intravenous and Subcutaneous Single Ascending Doses in Healthy Volunteers, and Subcutaneous Multiple Ascending Doses in Subjects With Painful Lumbar Radiculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety and tolerability of a range of&#xD;
      single intravenous (IV) and subcutaneous (SC) doses of BG00010 in healthy volunteers, and a&#xD;
      range of multiple SC doses of BG00010 in participants with painful lumbar radiculopathy.&#xD;
      Secondary objectives of this study are to determine the single IV and SC dose&#xD;
      pharmacokinetics (PK) profile of BG00010 in healthy volunteers including assessment of&#xD;
      bioavailability by comparing SC exposure to IV exposure in each participant, to determine the&#xD;
      multiple SC dose PK profiles of BG00010 in participants with painful lumbar radiculopathy, to&#xD;
      assess the single IV and SC dose immunogenicity of BG00010 in healthy volunteers, to assess&#xD;
      the multiple SC dose immunogenicity of BG00010 in participants with painful lumbar&#xD;
      radiculopathy, and to assess the potential of BG00010 to reduce pain following multiple SC&#xD;
      administrations in participants with painful lumbar radiculopathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of participants with Adverse Events (AEs)/Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Day 75</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of BG00010</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum serum concentration (Tmax) of BG00010</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (t1/2) of BG00010</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration time curve (AUC) from zero to infinity AUC(0-∞) for BG00010</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subcutaneous (SC) bioavailability</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with anti-BG00010 antibodies in serum</measure>
    <time_frame>Up to Day 75</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as measured by an 11-point numeric rating scale (NRS)</measure>
    <time_frame>Up to Day 75</time_frame>
    <description>The Numeric Rating Scale (NRS-11) is an 11-point scale for patient self-reporting of pain. The scale ranges from 0 (no pain) to 10 (worst pain imaginable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as measured by short form McGill pain questionnaire (SF-MPQ) visual analog scale (VAS)</measure>
    <time_frame>Up to Day 75</time_frame>
    <description>A 10 cm visual analog scale ranging from 0 (no pain) to 10 (worst possible pain).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Painful Lumbar Radiculopathy</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose (SAD): BG00010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to five cohorts of healthy volunteers will receive a single dose of intravenous (IV) BG00010 followed by a single SC dose of BG00010 2 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD: Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to five cohorts of healthy volunteers will receive a single IV dose of placebo followed by a single SC dose of placebo 2 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose (MAD): BG00010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 6 cohorts of participants with painful lumbar radiculopathy will receive 3 SC doses of BG00010.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose (MAD): Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 6 cohorts of participants with painful lumbar radiculopathy will receive 3 SC doses of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BG00010 IV</intervention_name>
    <description>Ascending Doses intravenous (IV) of BG00010</description>
    <arm_group_label>Single Ascending Dose (SAD): BG00010</arm_group_label>
    <other_name>Neublastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BG00010 SC</intervention_name>
    <description>Ascending Doses subcutaneous (SC) of BG00010</description>
    <arm_group_label>Multiple Ascending Dose (MAD): BG00010</arm_group_label>
    <arm_group_label>Single Ascending Dose (SAD): BG00010</arm_group_label>
    <other_name>Neublastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IV</intervention_name>
    <description>Ascending Doses intravenous (IV) of Placebo</description>
    <arm_group_label>SAD: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo SC</intervention_name>
    <description>Ascending Doses subcutaneous (SC) of placebo</description>
    <arm_group_label>Multiple Ascending Dose (MAD): Placebo</arm_group_label>
    <arm_group_label>SAD: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria: Part I and Part II&#xD;
&#xD;
          -  Healthy Volunteers&#xD;
&#xD;
        Key Inclusion Criteria: Part III multiple ascending dose (MAD)&#xD;
&#xD;
          -  Subjects must have a diagnosis of unilateral painful lumbar radiculopathy and painful&#xD;
             lumbar radiculopathy symptoms must be present for 3 or more months prior to the&#xD;
             Screening Visit.&#xD;
&#xD;
          -  Subjects must rate their pain at ≥40 mm on the 100 mm visual analog scale (VAS) of the&#xD;
             short form McGill pain questionnaire (SF-MPQ) at the Screening and Baseline Visits.&#xD;
&#xD;
        Key Inclusion Criteria for All Subjects for Part I, Part II, Part III:&#xD;
&#xD;
          -  All male subjects and all female subjects of childbearing potential must practice&#xD;
             effective contraception during the study and be willing and able to continue&#xD;
             contraception for 3 months after their last dose of study treatment. -&#xD;
&#xD;
        Key Exclusion Criteria for All Subjects for Part I, Part II, Part III:&#xD;
&#xD;
          -  History of or positive screening test for hepatitis C infection , hepatitis B&#xD;
             infection, or positive for human immunodeficiency virus (HIV) antibody. Subjects who&#xD;
             are hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (HBcAb)&#xD;
             positive are allowed to participate if they are positive for HBsAb immunoglobulin G&#xD;
&#xD;
          -  History of malignancy or clinically relevant (as determined by the Investigator)&#xD;
             allergies; cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic,&#xD;
             urologic, pulmonary, neurologic (not related to painful lumbar radiculopathy),&#xD;
             dermatologic, rheumatic/joint, psychiatric, renal, and/or other major disease.&#xD;
&#xD;
          -  Relevant history of illicit drug or alcohol abuse (as defined by the Investigator)&#xD;
             within 1 year prior to the Screening Visit. -&#xD;
&#xD;
          -  Female subjects who are pregnant or currently breastfeeding, or who have a positive&#xD;
             pregnancy test result at the Screening or Baseline Visits.&#xD;
&#xD;
          -  Previous administration of a neurotrophic factor, including BG00010.&#xD;
&#xD;
          -  Participation in a study with another investigational drug or approved therapy for&#xD;
             investigational use within the 3 months prior to the Baseline Visit, or current&#xD;
             enrollment in any other study.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>April 25, 2013</study_first_submitted>
  <study_first_submitted_qc>April 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2013</study_first_posted>
  <last_update_submitted>February 5, 2015</last_update_submitted>
  <last_update_submitted_qc>February 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sciatica</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiculopathy</mesh_term>
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

